Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 1905 results for carers

  1. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer TSID 12044

    Awaiting development [GID-TA11558] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Nirogacestat for treating desmoid tumours TSID 12039

    Awaiting development [GID-TA11559] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040

    Awaiting development [GID-TA11560] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

    In development [GID-TA11167] Expected publication date: 05 June 2024

    Technology appraisal guidance
    In development

  5. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: 05 December 2024

    Health technology evaluations
    In development

  7. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development [GID-TA11401] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Sodium zirconium cyclosilicate for the first line treatment of hyperkalaemia [ID6439]

    Awaiting development [GID-TA11561] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

    Awaiting development [GID-TA11019] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease ID6343

    In development [GID-TA11379] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure

    Awaiting development [GID-IPG10404] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  14. In-situ Normothermic Regional Perfusion system for DCD donors

    Awaiting development [GID-IPG10405] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  15. Insertion of neo-chordae into the beating heart for mitral regurgitation

    In development [GID-IPG10216] Expected publication date: TBC

    Interventional procedures guidance
    In development